| 國立成功大學 |
2023-06-23 |
Concise nanotherapeutic modality for cancer involving graphene oxide dots in conjunction with ascorbic acid
|
Shih;Chun-Yan;Wang;Pei-Ting;Chung;Wei-Pang;Wang;Wen-Hsiu;Chiang;I-Ting;Su;Wu-Chou;Huang;Wei-Lun;Teng;Hsisheng |
| 國立成功大學 |
2023-03-9 |
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
|
Chu;Chang-Yao;Lin;Chien-Yu;Lin;Chien-Chung;Li;Chien-Feng;Wu;Shang-Yin;Tsai;Jeng-Shiuan;Yang;Szu-Chun;Chen;Chian-Wei;Lin;Chia-Yin;Chang;Chao-Chun;Yen;Yi-Ting;Tseng;Yau-Lin;Su;Po-Lan;Su;Wu-Chou |
| 國立成功大學 |
2022-11 |
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
|
Tsai;Jeng-Shiuan;Wei;Sheng-Huan;Chen;Chian-Wei;Yang;Szu-Chun;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022-08-11 |
Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation
|
Chin;Yu-Cheng;Yang;Li-Xing;Hsu;Fei-Ting;Hsu;Che-Wei;Chang;Te-Wei;Chen;Hsi-Ying;Chen;Linda, Yen-Chien;Chia;Chun, Zi;Hung;Chun-Hua;Su;Wu-Chou;Chiu;Yi-Chun;Huang;Chih-Chia;Liao;Mei-Yi |
| 國立成功大學 |
2022-08 |
Development of a cancer cells self-activating and miR-125a-5p expressing poly-pharmacological nanodrug for cancer treatment
|
Chang;Yung-Chieh;Shieh;Min-Chieh;Chang;Yen-Hsuan;Huang;Wei-Lun;Su;Wu-Chou;Cheng;Fong-Yu;Cheung;Antonio, Chun Hei |
| 國立成功大學 |
2022-05-20 |
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naive Metastatic Lung Adenocarcinoma
|
Yang;Szu-Chun;Lin;Chien-Chung;Chen;Yi-Lin;Su;Wu-Chou |
| 國立成功大學 |
2022-02-28 |
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
|
Su;Po-Lan;Chen;Jung-Yueh;Chu;Chang-Yao;Chen;Yi-Lin;Chen;Wan-Li;Lin;Kuan-Yu;Ho;Chung-Liang;Tsai;Jeng-Shiuan;Yang;Szu-Chun;Chen;Chian-Wei;Wu;Yi-Lin;Tseng;Yau-Lin;Chang;Chao-Chun;Yen;Yi-Ting;Lin;Chia-Ying;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022-01-7 |
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
|
Chung;Wei-Pang;Huang;Wei-Lun;Liao;Wei-An;Hung;Chun-Hua;Chiang;Chi-Wu;Cheung;Antonio, Chun Hei;Su;Wu-Chou |
| 國立成功大學 |
2022-01 |
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors
|
Wang;Sheng-Yuan;Lai;Ching-Han;Chen;Chian-Wei;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Su;Po-Lan;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2022 |
PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
|
Chung;Wei-Pang;Huang;Wei-Lun;Lee;Chun-Hui;Hsu;Hui-Ping;Huang;Wan-Ling;Liu;You-Yu;Su;Wu-Chou |
| 國立成功大學 |
2022 |
Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy
|
Yang;Pei-Shan;Yu;Min-Hua;Hou;Ya-Chin;Chang;Chih-Peng;Lin;Shao-Chieh;Kuo;I-Ying;Su;Pei-Chia;Cheng;Hung-Chi;Su;Wu-Chou;Shan;Yan-Shen;Wang;Yi-Ching |
| 國立成功大學 |
2021-12 |
Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer
|
Huang;Yi-Hsuan;Lin;Peng-Chan;Su;Wu-Chou;Chan;Ren-Hao;Chen;Po-Chuan;Lin;Bo-Wen;Shen;Meng-Ru;Chen;Shang-Hung;Yeh;Yu-Min |
| 國立成功大學 |
2021-11 |
CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes
|
Yeh;Yu-Min;Lin;Peng-Chan;Su;Wu-Chou;Shen;Meng-Ru |
| 國立成功大學 |
2021-09-24 |
Development of a novel ALK rearrangement screening test for non-small cell lung cancers
|
Chen;Yi-Lin;Chen;Wan-Li;Cheng;Yi-Chia;Lin;Ming-Ching;Yang;Shu-Ching;Tsai;Hung-Wen;Lin;Chien-Chung;Su;Wu-Chou;Chow;Nan-Haw;Ho;Chung-Liang |
| 國立成功大學 |
2021-09 |
EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
|
Tsai;Jeng-Shiuan;Su;Po-Lan;Yang;Szu-Chun;Chang;Chao-Chun;Lin;Chia-Ying;Yen;Yi-Ting;Tseng;Yau-Lin;Lai;Wu-Wei;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2021-05-14 |
Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy
|
Shih;Chun-Yan;Huang;Wei-Lun;Chiang;I-Ting;Su;Wu-Chou;Teng;Hsisheng |
| 國立成功大學 |
2021-04 |
Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models
|
Chung;Wei-Pang;Huang;Wei-Lun;Liao;Wei-An;Huang;Wan-Ling;Liu;You-Yu;Su;Wu-Chou |
| 國立成功大學 |
2021-03-1 |
Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
|
Tsai;Hui-Jen;Shiah;Her-Shyong;Chang;Jang-Yang;Su;Wu-Chou;Chiang;Nai-Jung;Chen;Li-Tzong |
| 國立成功大學 |
2021-03 |
Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
|
Lin;Chien-Chung;Wu;Chin-You;Tseng;Joseph, Ta-Chien;Hung;Chun-Hua;Wu;Shang-Yin;Huang;Yu-Ting;Chang;Wei-Yuan;Su;Po-Lan;Su;Wu-Chou |
| 國立成功大學 |
2021-02 |
First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer
|
Su;Po-Lan;Chen;Chian-Wei;Wu;Yi-Lin;Lin;Chien-Chung;Su;Wu-Chou |
| 國立成功大學 |
2021-02 |
Nanomedicine-Based Strategies Assisting Photodynamic Therapy for Hypoxic Tumors: State-of-the-Art Approaches and Emerging Trends
|
Shih;Chun-Yan;Wang;Pei-Ting;Su;Wu-Chou;Teng;Hsisheng;Huang;Wei-Lun |
| 國立成功大學 |
2021 |
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment
|
Kuo;I-Ying;Yang;You-En;Yang;Pei-Shan;Tsai;Yu-Jou;Tzeng;Hong-Tai;Cheng;Hung-Chi;Kuo;Wan-Ting;Su;Wu-Chou;Chang;Chih-Peng;Wang;Yi-Ching |
| 國立成功大學 |
2020-10 |
Clinical Frailty Scale in Predicting Postoperative Outcomes in Older Patients Undergoing Curative Surgery for Urologic Malignancies: A Prospective Observational Cohort Study
|
Sun;Chien-Yao;Huang;Chien-Cheng;Tsai;Yuh-Shyan;Chang;Yu-Tzu;Ou;Chien-Hui;Su;Wu-Chou;Fan;Sheng-Yu;Wang;Shan-Tair;Yang;Deng-Chi;Huang;Chi-Chang;Chang;Chia-Ming |
| 國立成功大學 |
2020-08 |
Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients
|
Li;Feng;Wei;Fang;Huang;Wei-Lun;Lin;Chien-Chung;Li;Liang;Shen;Macy, Macy M.;Yan;Qingxiang;Liao;Wei;Chia;David;Tu;Michael;Tang;Jason, H.;Feng;Ziding;Kim;Yong;Su;Wu-Chou;Wong;David, T. W. |
| 國立成功大學 |
2020-07-16 |
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
|
Huang;Yi-Te;Chen;Ya-Ping;Lin;Wen-Chih;Su;Wu-Chou;Sun;Yuan-Ting |
